期刊文献+

High-level expression of recombinant IgG1 by CHO K1 platform

High-level expression of recombinant IgG1 by CHO K1 platform
原文传递
导出
摘要 The Chinese Hamster Ovary (CHO K1) cell was used to express a targeted anti-cancer monoclonal antibody by optimizing the platform of the construction of production cell line in this study. The adherent CHO K1 was first adapted to suspension culture in chemical defined medium. Then the glutamine synthetase (GS) vector was applied to construct a single plasmid to overexpress a monoclonal antibody IgG1. Post transfection, the produc- tion of cell pool was optimized by glutamine-free selection and amplification using various concentrations of methio- nine sulfoximine. The best cell pool ofCHO K1/IgG1 was used to screen the top single clone using the limiting dilution cloning. Finally, a high IgG1 production of 780 mg/L was obtained from a batch culture. This study demonstrated that the construction of high producing cell line, from gene to clone, could be completed within six month and the gene amplification improved protein production greatly. The Chinese Hamster Ovary (CHO K1) cell was used to express a targeted anti-cancer monoclonal antibody by optimizing the platform of the construction of production cell line in this study. The adherent CHO K1 was first adapted to suspension culture in chemical defined medium. Then the glutamine synthetase (GS) vector was applied to construct a single plasmid to overexpress a monoclonal antibody IgG1. Post transfection, the produc- tion of cell pool was optimized by glutamine-free selection and amplification using various concentrations of methio- nine sulfoximine. The best cell pool ofCHO K1/IgG1 was used to screen the top single clone using the limiting dilution cloning. Finally, a high IgG1 production of 780 mg/L was obtained from a batch culture. This study demonstrated that the construction of high producing cell line, from gene to clone, could be completed within six month and the gene amplification improved protein production greatly.
出处 《Frontiers of Chemical Science and Engineering》 SCIE EI CAS CSCD 2015年第3期376-380,共5页 化学科学与工程前沿(英文版)
关键词 Chinese hamster ovary (CHO) monoclonal antibody IGG1 amplification cell line development Chinese hamster ovary (CHO), monoclonal antibody, IgG1, amplification, cell line development
  • 相关文献

参考文献23

  • 1Leone-Bay A. Next-generation protein therapeutics summit con- ference report. Therapeutic Delivery, 2011, 2(10): 1233-1234.
  • 2Leader B, Baca Q J, Golan D E. Protein therapeutics: A summary and pharmacological classification. National Review, 2008, 7(1): 21-39.
  • 3Zhou L, Xu N, Sun Y, Liu X M. Targeted biopharmaceuticals for cancer treatment. Cancer Letters, 2014, 352(2): 145-151.
  • 4Edelman G M. Antibody structure and molecular immunology. Science, 1973, 180(4088): 830-840.
  • 5Chames P, Regenmortel M V, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 2009, 157:220-233.
  • 6Butler M, Spearman M. The choice of mammalian cell host and possibilities for glycosylation engineering. Current Opinion in Biotechnology, 2014, 30:107-112.
  • 7Zhang P, Chan K F, Haryadi R, Bardor M, Song Z. CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy. Advances in Biochemical Engi- neering/Biotechnology, 2013, 131 : 63 87.
  • 8Lai T, Yang Y, Ng S K. Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals, 2013, 6(5): 579-603.
  • 9Omasa T, Onitsuka M, Kim W D. Cell engineering and cultivation of Chinese Hamster Ovary (CHO) cells. Current Pharmaceutical Biotechnology, 2010, 11(3): 233-240.
  • 10Lewis N E, Liu X, Li Y, Nagarajan H, Yerganian G, O'Brien E,Bordbar A, Roth A M, Rosenbloom J, Bian C, Xie M, Chen W, Li N, Baycin-Hizal D, LatifH, Forster J, Betenbaugh M J, Famili I, Xu X, Wang J, Palsson B O. Genomic landscapes of Chinese hamster ovary cell lines as revealed by the Cricetulus griseus draft genome. Nature Biotechnology, 2013, 31(8): 759~65.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部